Because CLR01 may bind to Lys residues in proteins other than amyloid ?? and tau and affect their activity, we used several criteria, including appetite loss, weight loss (Table 1), lethargy and mortality to explore whether CLR01 treatment had adverse effects on the triple-transgenic mice.